Comparison of Propranolol and Octreotide in the Prophylaxis of Esophageal Variceal Bleeding in Children

Efficacy of propranolol compared to octreotide in the prophylactic treatment of patients with esophageal varices: A randomized clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260429069207N1

Enrollment

Registered

2026-05-05

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Hypertension and Esophageal Varices. Esophageal varices

Interventions

Intervention 1: Intervention group: Octreotide at a dose of 0.25 mg/kg monthly. Intervention 2: Control group: Propranolol at a dose of 1 mg/kg daily.

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Ages 1 to 18 Patients with portal hypertension (PHT) Patients with esophageal variceal bleeding

Exclusion criteria

Exclusion criteria: Children with asthma Children with diabetes Children with any type of cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Occurrence of the first episode of clinically or endoscopically confirmed esophageal variceal bleeding during the follow-up period. Timepoint: At the beginning and at the end of the study. Method of measurement: Endoscopic grading of esophageal varices.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Alimadadi

Tehran University of Medical Sciences

h_alimadadi@cina.tums.ac.ir+98 21 6147 9999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026